We found that in patients at risk for HCC, EpCAM or GPC‐3 biomarkers, such as those for HCC42 and HCC51, are not always expressed, indicating individual heterogeneity among HCC patients, which necessitates a comprehensive molecular assessment. Here, GPC3 is linked to hepatocellular carcinoma.